Hypopharyngeal Cancer
Pyriform sinus cancer · Postcricoid cancer · Lower throat cancer | ICD-O-3 C12–C13
Hypopharyngeal cancer arises in the lowest part of the throat, most often the pyriform sinus, beside and behind the voice box. It is uncommon worldwide but concentrated in South Asia and Eastern Europe, is strongly linked to tobacco and alcohol, and is usually diagnosed late because the space is silent until the tumour is large. Treatment commonly requires combined chemoradiotherapy or major surgery with reconstruction.
The hypopharynx is a funnel that channels food around the larynx into the oesophagus. Because it has generous space and rich lymphatic drainage, tumours can grow unnoticed and spread to neck nodes early. A painless neck mass, progressive difficulty swallowing or pain referred to the ear may be the first sign; hoarseness and breathing difficulty appear later when the larynx is involved.
Hypopharyngeal squamous cell carcinoma has among the least favourable outcomes of the head and neck subsites, largely because of advanced stage at presentation and the functional cost of treatment. Decisions about larynx preservation, reconstruction of the food passage and nutrition must be made by an experienced multidisciplinary team before the first treatment is given.
Where in the world is hypopharyngeal cancer common?
about 86,300 new hypopharyngeal cancer cases worldwide were estimated worldwide in 2022 (male ASR 1.6 and female ASR 0.3 per 100,000; 11.4% of all lip/oral/pharyngeal cancers in 2022).
The wider GLOBOCAN 2022 estimate (ICD-10 C12–C13) was 86,257 cases with an ASR of 0.89 per 100,000.
| Region / country | What the data show |
|---|---|
| Eastern Europe & the Baltic states | Hypopharyngeal cancer makes up 15.8% of the region’s lip/oral/pharyngeal burden — the highest regional share. Male ASRs above 5.0 are reported in Hungary, Slovakia, Belarus and Lithuania. |
| South-Central Asia / Bangladesh | 15.3% of the regional burden. Bangladesh has the highest ASR worldwide in both sexes (male 9.3, female 1.6); India’s ASIR is reported at 2.1 per 100,000. |
| India | High absolute burden from smoking, bidi use, chewing tobacco and alcohol, frequently with late-stage presentation and nutritional deficiency. |
| France & Western Europe | Historically elevated rates of hypopharyngeal and supraglottic cancer associated with combined tobacco and alcohol exposure. |
| North America & Australia | Rates are substantially lower and have generally declined with smoking cessation; the oropharynx (HPV-driven) is now the dominant pharyngeal subsite. |
What are the risk factors?
- Heavy, long-term tobacco smoking (cigarettes, bidis, pipes)
- Heavy alcohol use — the combination with tobacco is strongly synergistic
- Plummer–Vinson / Paterson–Kelly syndrome: iron-deficiency anaemia, oesophageal webs and postcricoid carcinoma
- Poor nutrition, low fruit and vegetable intake and micronutrient deficiency
- Occupational exposures and gastro-oesophageal reflux (weaker associations)
- Male sex and age over 50; prior head and neck radiotherapy
What are the signs and symptoms?
- Progressive difficulty or pain when swallowing solids (dysphagia, odynophagia)
- Persistent sore throat or a sensation of a lump in the throat
- Pain radiating to one ear (referred otalgia) with a normal ear examination
- A hard, painless lump in the neck — sometimes the only presenting sign
- Hoarseness, noisy breathing or aspiration in advanced disease
- Weight loss, fatigue and reduced oral intake
Two-to-three-week rule: any head or neck symptom that persists beyond two to three weeks should be examined by an ENT specialist with an endoscope — pain is usually a late feature, not an early one.
How is it diagnosed and staged?
- Flexible nasopharyngolaryngoscopy to inspect the pyriform sinus, postcricoid region and vocal cord mobility
- Fine-needle aspiration of a neck mass; avoid open biopsy of a nodal metastasis
- Panendoscopy (laryngoscopy, oesophagoscopy, bronchoscopy) with biopsy under general anaesthesia
- Contrast CT and/or MRI of the neck and chest; FDG PET-CT for advanced nodal or distant disease
- Nutritional assessment, swallowing evaluation and dental review before treatment
- Tumour board review, because synchronous oesophageal lesions and second primary tumours must be excluded
TNM staging for hypopharyngeal cancer reflects tumour size, number and size of neck nodes, and distant metastasis. Involvement of the pyriform apex, postcricoid region, vocal cord fixation or thyroid/cricoid cartilage generally indicates T3–T4a disease and often removes the option of partial laryngopharyngectomy.
What are the treatment options?
- Early T1–T2 N0 disease: primary radiotherapy or larynx-preserving partial laryngopharyngectomy with selective neck dissection
- Locally advanced disease: concurrent cisplatin-based chemoradiotherapy, or induction chemotherapy followed by response-adapted radiotherapy/chemoradiotherapy
- Total laryngopharyngectomy with neck dissection and reconstruction (free jejunal transfer, anterolateral thigh flap or gastric pull-up) for T4a or non-responders
- Postoperative radiotherapy for close margins, multiple nodes or perineural invasion; concurrent chemoradiotherapy for positive margins or extranodal extension
- Enteral feeding support (nasogastric tube or gastrostomy), speech and swallow rehabilitation, and airway management
- Recurrent/metastatic disease: PD-1 immunotherapy, chemotherapy, clinical trials or palliative radiotherapy
Decisions should be made by a multidisciplinary tumour board, with speech, swallowing and appearance considered alongside cancer control. See how treatment changes with stage →
What is the prognosis?
Because most patients present with stage III–IV disease, five-year survival for hypopharyngeal cancer is commonly reported in the 30–50% range — lower than for glottic laryngeal cancer. Small T1–T2 tumours treated with a single modality do considerably better. Nutritional status, swallowing function, nodal burden and treatment interruptions all influence outcome.
Survival figures are population averages from registry data, not predictions for an individual. See the follow-up schedule →
Can it be prevented?
- Stop smoking and heavy alcohol use — the dominant modifiable risks
- Diagnose and treat iron-deficiency anaemia and Plummer–Vinson syndrome
- Improve nutrition and maintain a diet rich in fruit and vegetables
- Assess persistent swallowing pain or a neck lump with endoscopy rather than empirical acid suppression alone
- Stopping tobacco after treatment also reduces second-primary tumours in the upper aerodigestive tract
Prevention by region: HPV vaccine, areca nut, tobacco and UV →
Treatment in China for international patients
International patients with hypopharyngeal cancer are usually evaluated for either organ-preserving chemoradiotherapy or total laryngopharyngectomy with immediate reconstruction of the food passage. Chinese tertiary centres with head and neck reconstructive teams can perform the ablative and reconstructive stages in a single operation.
- Bring biopsy slides, panendoscopy notes, contrast CT/MRI on DICOM, PET-CT if done, and a nutritional/swallowing assessment.
- Ask specifically how the pharynx will be reconstructed, whether a permanent stoma or feeding tube is expected, and what speech and swallowing rehabilitation is available.
- Request a written explanation of why larynx preservation was or was not chosen, plus the chemotherapy and radiotherapy doses in English.
- Plan for a longer stay: major pharyngeal reconstruction and postoperative radiotherapy can require 8–12 weeks.
Cost guidance: As an illustrative planning range, total laryngopharyngectomy with free-flap reconstruction is commonly budgeted at ¥130,000–¥260,000 (about US$18,000–36,000); definitive concurrent chemoradiotherapy ¥110,000–¥220,000. Nutrition support, stoma supplies and rehabilitation are additional. These figures are not a quotation.
Compare the pathway, records checklist and aftercare planning on the international patients page.
All 13 questions about hypopharyngeal cancer
Each question has its own page with a direct answer, practical detail and the sources behind it — the same structure used on Dr. Liu’s Chinese knowledge base.
Understanding the disease
4 questionsWhat the tumour is, where in the world it is common, who gets it and why.
Symptoms & diagnosis
2 questionsThe warning signs, the biopsy, the scans and what staging actually means.
Treatment
2 questionsSurgery, radiotherapy, chemotherapy, immunotherapy and organ-preserving options.
Side effects & recovery
1 questionWhat treatment feels like, how side effects are managed, and rehabilitation.
Prognosis & follow-up
1 questionSurvival figures in context, recurrence risk and the follow-up schedule.
Prevention & risk
2 questionsHPV vaccination, tobacco and areca nut, UV protection and occupational exposure.
Treatment in China
1 questionWhat international patients should prepare, timelines, costs and aftercare.
Frequently asked questions
What is hypopharyngeal cancer?
Hypopharyngeal cancer arises in the lowest part of the throat, most often the pyriform sinus, beside and behind the voice box. It is uncommon worldwide but concentrated in South Asia and Eastern Europe, is strongly linked to tobacco and alcohol, and is usually diagnosed late because the space is silent until the tumour is large. Treatment commonly requires combined chemoradiotherapy or major surgery with reconstruction.
Where in the world is hypopharyngeal cancer most common?
Hypopharyngeal Cancer is not evenly distributed: the highest-burden regions are Eastern Europe & the Baltic states, South-Central Asia / Bangladesh and India. In 2022 there were about 86,300 new hypopharyngeal cancer cases worldwide worldwide (male ASR 1.6 and female ASR 0.3 per 100,000; 11.4% of all lip/oral/pharyngeal cancers in 2022), with marked country-to-country variation driven by local exposures such as tobacco, areca nut, oncogenic viruses, ultraviolet radiation and occupational carcinogens.
What are the risk factors for hypopharyngeal cancer?
The main recognised risk factors for hypopharyngeal cancer are heavy, long-term tobacco smoking (cigarettes, bidis, pipes), heavy alcohol use — the combination with tobacco is strongly synergistic and plummer–Vinson / Paterson–Kelly syndrome: iron-deficiency anaemia, oesophageal webs and postcricoid carcinoma. Risks differ by region: Eastern Europe & the Baltic states has a distinctive exposure pattern, so a patient's country of residence is part of the risk assessment. Having a risk factor does not mean a person will develop cancer.
What are the early signs of hypopharyngeal cancer?
The common early signs are progressive difficulty or pain when swallowing solids (dysphagia, odynophagia), persistent sore throat or a sensation of a lump in the throat, pain radiating to one ear (referred otalgia) with a normal ear examination and a hard, painless lump in the neck — sometimes the only presenting sign. Head and neck tumours often cause mild, one-sided symptoms that mimic a cold, a dental problem or a sore throat. Any symptom in the head or neck that persists for more than two to three weeks needs an ENT examination rather than repeated antibiotics.
How is hypopharyngeal cancer diagnosed and staged?
Diagnosis requires a tissue biopsy read by a head and neck pathologist, supported by endoscopic examination and contrast CT or MRI of the neck; PET-CT is added when nodal or distant spread is suspected. Staging uses the AJCC TNM system and guides whether surgery, radiotherapy, chemoradiotherapy or systemic therapy is the primary treatment.
What are the treatment options for hypopharyngeal cancer?
Treatment is stage- and site-specific, and usually combines early T1–T2 N0 disease: primary radiotherapy or larynx-preserving partial laryngopharyngectomy with selective neck dissection, locally advanced disease: concurrent cisplatin-based chemoradiotherapy, or induction chemotherapy followed by response-adapted radiotherapy/chemoradiotherapy and total laryngopharyngectomy with neck dissection and reconstruction (free jejunal transfer, anterolateral thigh flap or gastric pull-up) for T4a or non-responders. Early-stage disease is generally treated with one modality (surgery or radiotherapy), while locally advanced disease needs combined modality treatment planned by a multidisciplinary team.
What is the prognosis for hypopharyngeal cancer?
Because most patients present with stage III–IV disease, five-year survival for hypopharyngeal cancer is commonly reported in the 30–50% range — lower than for glottic laryngeal cancer. Small T1–T2 tumours treated with a single modality do considerably better. Nutritional status, swallowing function, nodal burden and treatment interruptions all influence outcome.
Can hypopharyngeal cancer be prevented?
Many cases are preventable. The most useful steps for hypopharyngeal cancer are stop smoking and heavy alcohol use — the dominant modifiable risks, diagnose and treat iron-deficiency anaemia and Plummer–Vinson syndrome and improve nutrition and maintain a diet rich in fruit and vegetables. Prevention works best before exposure begins, but stopping tobacco, areca nut and heavy alcohol use still lowers risk after many years of use.
Why is hypopharyngeal cancer usually found at an advanced stage?
The hypopharynx is a wide, relatively insensitive funnel, so a tumour can grow substantially before it obstructs swallowing or causes pain. Its rich lymphatic network also allows early spread to neck nodes, meaning a painless neck lump may be the first sign while the primary tumour remains symptomless.
What is Plummer–Vinson syndrome and how is it linked to hypopharyngeal cancer?
Plummer–Vinson (Paterson–Kelly) syndrome is the combination of iron-deficiency anaemia, dysphagia from oesophageal webs and glossitis. It is a recognised risk factor for postcricoid hypopharyngeal and upper oesophageal squamous cell carcinoma, particularly in women, and is one reason postcricoid tumours have a distinct epidemiological profile.
How is the throat reconstructed after hypopharyngeal cancer surgery?
When the hypopharynx and larynx are removed, the food passage must be rebuilt. Common options are a free jejunal transfer (a segment of small bowel with its vessels reconnected in the neck), a tubed anterolateral thigh or radial forearm free flap, or a gastric pull-up when the oesophagus is also involved. The choice depends on the defect length, prior surgery and general fitness.
Will I be able to eat and swallow normally after treatment?
Swallowing is commonly affected, but most patients regain at least soft or full oral intake with rehabilitation. Chemoradiotherapy can cause strictures, fibrosis and chronic dysphagia; major reconstruction requires a structured swallowing programme and often temporary tube feeding while the new conduit heals.
What is the likely cost of hypopharyngeal cancer treatment in China?
Illustrative planning ranges are ¥130,000–¥260,000 (about US$18,000–36,000) for total laryngopharyngectomy with free-flap reconstruction and ¥110,000–¥220,000 for definitive concurrent chemoradiotherapy. Nutritional support, speech/swallow therapy and stoma supplies are usually billed separately.
Sources for this topic
- Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022
- Head and neck cancer: a comprehensive review of epidemiology, global burden and advances in radiotherapy
- Global Cancer Observatory (GLOBOCAN 2022)
- Hypopharyngeal Cancer Treatment (PDQ, health professional version)
- NCCN Guidelines for Patients: Head and Neck Cancers
- Nivolumab Risk Management Plan — epidemiological characteristics of SCCHN (GLOBOCAN 2022 summary)
Ask about hypopharyngeal cancer treatment in China
Send your pathology report, biomarker results and imaging for a written preliminary opinion before making travel plans.
What to send Contact the clinicMedical disclaimer: This knowledge base is general information for people researching head and neck tumours, not a diagnosis or treatment plan. It does not replace an examination by a qualified physician. Survival figures are population averages, not predictions for an individual. Treatment and cost estimates for China are illustrative only and must be confirmed in writing after your records have been reviewed. If you have a symptom lasting more than two to three weeks, see a doctor promptly.